NCI-2022-07395

A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors

This is an early-stage, open-label medical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of LY3176150, an investigational drug, in combination with pembrolizumab. LY3176150 is a type of drug called a RET inhibitor. RET inhibitors target a protein called RET, which can play a role in the growth and survival of cancer cells. Pembrolizumab is a type of immunotherapy drug called a PD-1 inhibitor. It helps the immune system attack cancer cells by blocking a protein called PD-1 that can sometimes hide cancer cells from the immune system. The study is open to adults with advanced solid tumors who have not received prior treatment with a RET inhibitor or anti-PD-1 therapy.

Early-stage: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

Open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05377528

NCI-2022-07395

Clinical Trial Site: Sinai

To see all available clinical trials click here.